Format

Send to

Choose Destination
Head Neck. 2016 Apr;38 Suppl 1:E2151-8. doi: 10.1002/hed.24026. Epub 2015 Jul 14.

Cumulative cisplatin dose in concurrent chemoradiotherapy for head and neck cancer: A systematic review.

Author information

1
Department of Radiation Oncology, Institute of Oncology, Ljubljana, Slovenia.
2
Department of Medical Oncology, Antwerp University Hospital, Edegem, Belgium.
3
Departments of Radiation Oncology, Otolaryngology, and Medical Oncology, Emory University School of Medicine, Atlanta, Georgia.
4
Department of Hematology and Medical Oncology, The Winship Cancer Institute of Emory University, Atlanta, Georgia.
5
Department of Medicine, Division of Oncology, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, New York.
6
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
7
Department of Internal Medicine, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan.
8
Department of Radiation Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
9
Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan.
10
Department of Radiation Oncology, University of Florida, Gainesville, Florida.
11
Center of Clinical Oncology, University of Hong Kong - Shenzhen Hospital, Shenzhen, China.
12
Department of Radiation Oncology, Beth Israel Medical Center and St Luke's-Roosevelt Hospitals, New York, New York.
13
Department of Otolaryngology-Head and Neck Surgery, University of Michigan, Ann Arbor, Michigan.
14
Department of Radiation Oncology, The Prince of Wales Cancer Centre, Sydney, New South Wales, Australia.
15
Departments of Surgery and Otolaryngology-Head and Neck Surgery, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, New York.
16
University of Udine School of Medicine, Udine, Italy.

Abstract

BACKGROUND:

The optimal cumulative dose and timing of cisplatin administration in various concurrent chemoradiotherapy protocols for nonmetastatic head and neck squamous cell carcinoma (HNSCC) has not been determined.

METHODS:

The absolute survival benefit at 5 years of concurrent chemoradiotherapy protocols versus radiotherapy alone observed in prospective randomized trials reporting on the use of cisplatin monochemotherapy for nonnasopharyngeal HNSCC was extracted. In the case of nonrandomized studies, the outcome results at 2 years were compared between groups of patients receiving different cumulative cisplatin doses.

RESULTS:

Eleven randomized trials and 7 nonrandomized studies were identified. In 6 definitive radiotherapy phase III trials, a statistically significant association (p = .027) between cumulative cisplatin dose, independent of the schedule, and overall survival benefit was observed for higher doses.

CONCLUSION:

Results support the conclusion that the cumulative dose of cisplatin in concurrent chemoradiation protocols for HNSCC has a significant positive correlation with survival. © 2015 Wiley Periodicals, Inc. Head Neck 38: E2151-E2158, 2016.

KEYWORDS:

cisplatin; concurrent chemoradiotherapy; cumulative dose; outcome; radiotherapy

PMID:
25735803
DOI:
10.1002/hed.24026
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Wiley Icon for MLibrary (Deep Blue)
Loading ...
Support Center